---
title: "CD19-CAR T-cell therapy and the EBV+ autoreactive B cell repertoire in autoimmune disease"
id: "biorxiv-8-cd19-car-t-cell-therapy-resets-the-ebv-autoreactive-b-cell-repertoire-in"
canonical_url: "https://medichelpline.com/clinical-feed/biorxiv-8-cd19-car-t-cell-therapy-resets-the-ebv-autoreactive-b-cell-repertoire-in"
content_type: "clinical_feed_article"
specialty: "Rheumatology"
source_name: "bioRxiv (Biomedical Preprints)"
source_url: "https://www.biorxiv.org/content/10.64898/2026.10.24.761515v1?rss=1"
published_at: "2026-11-02T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# CD19-CAR T-cell therapy and the EBV+ autoreactive B cell repertoire in autoimmune disease
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/biorxiv-8-cd19-car-t-cell-therapy-resets-the-ebv-autoreactive-b-cell-repertoire-in
- **Specialty:** [Rheumatology](https://medichelpline.com/clinical-feed/rheumatology.md)
- **Primary Source:** bioRxiv (Biomedical Preprints)
- **Source URL:** [Original Journal Publication](https://www.biorxiv.org/content/10.64898/2026.10.24.761515v1?rss=1)
- **Published At:** 2026-11-02T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The preprint title states that **CD19-CAR T-cell therapy** “resets” the **EBV+ autoreactive B cell** repertoire in autoimmune disease. This is the primary claim reported in the source title. - The article is posted on bioRxiv as a preprint and has not been peer-reviewed; the authors and their affiliations are listed on the preprint page. - The author list includes investigators affiliated with Stanford University, Leiden University Medical Center, FAU Erlangen-Nurnberg, Erlangen University Hospital, University Hospital of Erlangen, and other institutions; multiple individual author ORCIDs are provided. - The source did not report experimental details in the excerpt provided to this rewrite: specific patient populations, inclusion criteria, dosing, CAR construct sequence, manufacturing or infusion protocols, timelines, clinical endpoints, quantitative outcomes, statistical analyses, adverse event data, or sample sizes were not present in the supplied text. - The preprint DOI is given on the source page; bibliographic metadata are available, but substantive results and methods were not included in the supplied content. - Because detailed methods, results, and endpoints are absent from the provided source content, any interpretation of efficacy, safety, or mechanism beyond the title claim cannot be derived from this text alone. - Readers should consult the full preprint for experimental methods, cohort characteristics, outcome measures, and raw data before drawing clinical or translational conclusions. - The available information is limited to title-level claim, author affiliations, and preprint provenance; these points frame the clinical question but do not permit evidence-based appraisal from the excerpt provided.
## Clinical Analysis & Structured Key Points
CD19-CAR T-cell therapy resets the EBV+ autoreactive B cell repertoire in autoimmune disease | bioRxiv Skip to main content New Results CD19-CAR T-cell therapy resets the EBV+ autoreactive B cell repertoire in autoimmune disease View ORCID Profile Ya'el Courtney , View ORCID Profile Mahesh Pandit , View ORCID Profile Laura S van Dam , View ORCID Profile Shady Younis , View ORCID Profile Sajede Rasouli , Mengrui Zhang , View ORCID Profile Yashaar Chaichian , View ORCID Profile Shima Parsafar , View ORCID Profile Tobias V Lanz , View ORCID Profile Eline Arends , View ORCID Profile Cees van Kooten , View ORCID Profile Y. K. Onno Teng , View ORCID Profile Melanie Hagen , View ORCID Profile Andreas Wirsching , View ORCID Profile Fabian Muller , View ORCID Profile Andreas Mackensen , View ORCID Profile Aline Bozec , View ORCID Profile Ricardo Grieshaber-Bouyer , View ORCID Profile Georg Schett , View ORCID Profile William H Robinson doi: https://doi.org/10.64898/2026.10.24.761515 Ya'el Courtney 1 Stanford University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Ya'el Courtney Mahesh Pandit 1 Stanford University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Mahesh Pandit Laura S van Dam 1 Stanford University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Laura S van Dam Shady Younis 1 Stanford University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Shady Younis Sajede Rasouli 2 Stanford University, School Of Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Sajede Rasouli Mengrui Zhang 1 Stanford University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Yashaar Chaichian 1 Stanford University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Yashaar Chaichian Shima Parsafar 1 Stanford University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Shima Parsafar Tobias V Lanz 3 Stanford School of Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Tobias V Lanz Eline Arends 4 Leiden University Medical Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Eline Arends Cees van Kooten 4 Leiden University Medical Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Cees van Kooten Y. K. Onno Teng 4 Leiden University Medical Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Y. K. Onno Teng Melanie Hagen 5 FAU Erlangen-Nurnberg; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Melanie Hagen Andreas Wirsching 5 FAU Erlangen-Nurnberg; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Andreas Wirsching Fabian Muller 5 FAU Erlangen-Nurnberg; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Fabian Muller Andreas Mackensen 6 Erlangen University Hospital: Universitatsklinikum Erlangen; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Andreas Mackensen Aline Bozec 7 University Hospital of Erlangen; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Aline Bozec Ricardo Grieshaber-Bouyer 8 Friedrich-Alexander-Universitat Erlangen-Nurnberg; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Ricardo Grieshaber-Bouyer Georg Schett 9 FAU - Universitatsklinikum Erlangen Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Georg Schett William H Robinson 1 Stanford University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for William H Robinson For correspondence: wrobins{at}stanford.edu Abstract Info/History Metrics Supplementary material Preview PDF Abstract Epstein-Barr virus (EBV) reprograms autoreactive B cells into activated antigen-presenting cells that drive pathogenic T- and B-cell responses in autoimmune disease. Using EBV B-cell sequencing (EBV-seq), we profiled EBV+ B cells in patients treated with CD19 chimeric antigen receptor (CAR) T cells (systemic lupus, n=6; idiopathic inflammatory myopathies, n=3; systemic sclerosis, n=3) or rituximab (n=15). CAR T cells, but not rituximab, depleted EBV+ B cells, resetting the repertoire toward a naive state: predominantly IgM+ with minimal somatic hypermutation. Post-rituximab B-cells remained class-switched, hypermutated, and activated. Monoclonal antibodies cloned from EBV+ B cells lost autoreactivity after CAR T cells but not rituximab. Sustained drug-free remission occurred in 8/12 CAR-treated but 0/15 rituximab-treated patients. EBV+ B cells were predominantly Latency III and resisted anti-CD20 and anti-CD19 antibodies, yet were killed by CAR T cells and T-cell engagers. CD19-CAR T-cell therapy resets the autoreactive EBV+ B-cell repertoire, which may underlie sustained drug-free remission. Competing Interest Statement Y.C. holds a stock grant in Ebvio Inc. and has consulted for Ebvio Inc. S.Y., T.V.L., and W.H.R. are co-founders and stockholders in Ebvio Inc. T.V.L. and W.H.R. are co-founders and stockholders in Flatiron Bio LLC. W.H.R. is a director of Ebvio Inc and of Flatiron Bio LLC. F.M. has received research support from AstraZeneca, BMS, Kite/Gilead, and Miltenyi Bioscience, has consulted for AstraZeneca, ArgoBio, BMS, CRISPR Therapeutic, EcoR1, Incyte, Janssen, Kite/Gilead, Miltenyi Bioscience, Novartis, and Sobi and has received speakers honoraria from Abbvie, AstraZeneca, Beigene, BMS, Incyte, Janssen, Kite/Gilead, Miltenyi Bioscience, MSD, Novartis, Pfizer, Sobi, and Takeda. M.H. has received speakers honoraria from BMS, AstraZeneca, Century and Lilly, which are not related to this study. Y.Ch. receives research support from Lupus Therapeutics and the Lupus Research Alliance, previously received research support from Eli Lilly and Company, and Amgen Inc., and has served as a speaker providing non-branded SLE educational content through PeerDirect, which were not related to this study. A.M. has received speaker honoraria from BMS, Celgene, Gilead, Janssen, KITE, Miltenyi Biomedicine and Novartis, which were not related to this study. G.S. has received speaker honoraria from BMS, Cabaletta, Janssen, Kyverna and Novartis and UCB, which were not related to this study. Funder Information Declared National Institute of Allergy and Infectious Diseases , R01 AI173189 National Institute of Arthritis and Musculoskeletal and Skin Diseases , R01 AR078268 National Heart Lung and Blood Institute, https://ror.org/012pb6c26 , PATHO-PH2-SUB_17_23 Deutsche Forschungsgemeinschaft , CRC1755-CASCAID, grant number 550296805 Copyright The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Back to top Previous Next Posted November 02, 2026. Download PDF Supplementary Material Email Thank you for your interest in spreading the word about bioRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following CD19-CAR T-cell therapy resets the EBV+ autoreactive B cell repertoire in autoimmune disease Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share CD19-CAR T-cell therapy resets the EBV+ autoreactive B cell repertoire in autoimmune disease Ya'el Courtney , Mahesh Pandit , Laura S van Dam , Shady Younis , Sajede Rasouli , Mengrui Zhang , Yashaar Chaichian , Shima Parsafar , Tobias V Lanz , Eline Arends , Cees van Kooten , Y. K. Onno Teng , Melanie Hagen , Andreas Wirsching , Fabian Muller , Andreas Mackensen , Aline Bozec , Ricardo Grieshaber-Bouyer , Georg Schett , William H Robinson bioRxiv 2026.10.24.761515; doi: https://doi.org/10.64898/2026.10.24.761515 Share This Article: Copy Citation Tools CD19-CAR T-cell therapy resets the EBV+ autoreactive B cell repertoire in autoimmune disease Ya'el Courtney , Mahesh Pandit , Laura S van Dam , Shady Younis , Sajede Rasouli , Mengrui Zhang , Yashaar Chaichian , Shima Parsafar , Tobias V Lanz , Eline Arends , Cees van Kooten , Y. K. Onno Teng , Melanie Hagen , Andreas Wirsching , Fabian Muller , Andreas Mackensen , Aline Bozec , Ricardo Grieshaber-Bouyer , Georg Schett , William H Robinson bioRxiv 2026.10.24.761515; doi: https://doi.org/10.64898/2026.10.24.761515 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Animal Behavior and Cognition (8164) Biochemistry (19027) Bioengineering (15171) Bioinformatics (45567) Biophysics (22958) Cancer Biology (20191) Cell Biology (27406) Clinical Trials Developmental Biology (14191) Ecology (21472) Epidemiology (2067) Evolutionary Biology (25883) Genetics (16396) Genomics (23911) Immunology (19101) Microbiology (43361) Molecular Biology (18424) Neuroscience (95500) Paleontology (715) Pathology (3046) Pharmacology and Toxicology (5224) Physiology (8308) Plant Biology (16326) Scientific Communication and Education (2120) Synthetic Biology (4663) Systems Biology (10425) Zoology (2432)
## Related Clinical Research

- [COVID-19 Burden in Adults with Systemic Autoimmune Rheumatic Diseases in Quebec, 2020–2023](https://medichelpline.com/clinical-feed/medrxiv-15-comparative-burden-of-covid-19-in-adults-with-rheumatic-diseases-and.md)
- [Inebilizumab for AQP4-IgG–Positive NMOSD with Coexisting Autoimmunity: Two Case Reports](https://medichelpline.com/clinical-feed/frontiers-in-immunology-17-case-report-inebilizumab-in-aqp4-igg-positive-neuromyelitis-optica-spectrum.md)
- [Guideline differences in rheumatoid arthritis-associated interstitial lung disease care](https://medichelpline.com/clinical-feed/pubmed-42888356.md) (DOI: 10.1007/s00296-026-06322-x)
- [B-cell centrality and therapeutic response in autoimmune diseases: systematic review overview](https://medichelpline.com/clinical-feed/frontiers-in-immunology-10-b-cell-centrality-dictates-therapeutic-efficacy-across-autoimmune-diseases-a.md)
- [Coronary microvascular and myocardial involvement in granulomatosis with polyangiitis: an immunoca](https://medichelpline.com/clinical-feed/pubmed-42649433.md) (DOI: 10.1007/s00296-026-06282-2)

## Navigation
- [← Back to Rheumatology Feed](https://medichelpline.com/clinical-feed/rheumatology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.